Announcement • Dec 17
bioXXmed AG, Annual General Meeting, Jan 22, 2025 bioXXmed AG, Annual General Meeting, Jan 22, 2025, at 11:00 W. Europe Standard Time. Reported Earnings • Oct 30
First half 2024 earnings released: €0.70 loss per share (vs €0.60 loss in 1H 2023) First half 2024 results: €0.70 loss per share (further deteriorated from €0.60 loss in 1H 2023). Net loss: €362.1k (loss widened 17% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 17 percentage points per year, which is a significant difference in performance. New Risk • Apr 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m (€21k revenue, or US$22k). Market cap is less than US$10m (€2.41m market cap, or US$2.57m). Minor Risk Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). New Risk • Oct 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m (€12k revenue, or US$13k). Market cap is less than US$10m (€6.06m market cap, or US$6.39m). Minor Risk Share price has been volatile over the past 3 months (7.1% average weekly change). New Risk • Jul 02
New major risk - Revenue and earnings growth Earnings have declined by 22% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 22% per year over the past 5 years. Revenue is less than US$1m (€12k revenue, or US$13k). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Market cap is less than US$100m (€11.0m market cap, or US$12.0m). Reported Earnings • Jul 01
Full year 2022 earnings released Full year 2022 results: Net loss: €829.8k (loss narrowed 80% from FY 2021). Reported Earnings • Sep 03
First half 2022 earnings released: EPS: €0 (vs €0 in 1H 2021) First half 2022 results: EPS: €0 (vs €0 in 1H 2021). Net loss: €480.1k (loss narrowed 20% from 1H 2021). Reported Earnings • Jul 02
Full year 2021 earnings released Full year 2021 results: Net loss: €4.06m (loss widened 121% from FY 2020). Reported Earnings • Oct 05
First half 2021 earnings released First half 2021 results: Net loss: €601.1k (loss narrowed 13% from 1H 2020). Reported Earnings • Jul 04
Full year 2020 earnings released Full year 2020 results: Net loss: €1.84m (loss widened 44% from FY 2019). Announcement • Jun 22
CytoTools AG's Licensing Partner Centaur Pharmaceuticals Inc. Receives Tentative Approval for Woxheal(R) in Kenya, Africa CytoTools AG received a trading update on the first quarter of 2021 from its licensing partner Centaur Pharmaceuticals on the drug Woxheal(R) for the treatment of the Diabetic Foot Syndrome. According to the update, despite significant pandemic-related sales hinderances, sales of Woxheal(R) in India have increased slightly to over 10,000 use cases compared to the fourth quarter of 2020. In addition, Centaur Pharmaceuticals has informed the Company that it has now received tentative approval for Woxheal(R) in Kenya, Africa. Provisional approval of a drug can be granted in Kenya without additional studies based on the approval of the India Central Drugs Standard Control Organization (CDSCO). In parallel, Centaur is seeking approval for the drug in other African countries where a basically similar approval process is possible. Despite delays due to the progress of COVID-19 in Europe, the Management Board assesses the current progress of the study as still on track. Therefore, the company still expects to be able to report interim results of the study at the end of 2021 and then to successfully complete Phase III by the end of 2022. Announcement • Feb 23
CytoTools AG and Centaur Pharmaceuticals Achieves A Good Start to the Marketing of Its Active Ingredient for the Treatment of Diabetic Foot Syndrome in India CytoTools AG together with its licensing partner Centaur Pharmaceuticals, has achieved a good start to the marketing of its active ingredient for the treatment of diabetic foot syndrome in India. The market launch of the drug, which is marketed in India under the brand name Woxheal(R), was clearly overshadowed by the high prevalence of COVID-19 in India and the associated travel restrictions. However, given the severely limited opportunities to market the new drug through on-site sales appointments, the number of treatments performed is very promising. Is New 90 Day High Low • Feb 18
New 90-day low: €14.80 The company is down 24% from its price of €19.35 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €633 per share. Price Target Changed • Nov 19
Price target raised to €36.72 Up from €32.04, the current price target is an average from 2 analysts. The new target price is 81% above the current share price of €20.30. As of last close, the stock is up 89% over the past year. Announcement • Nov 14
CytoTools AG Receives the Preliminary Results of the Test Series with the Active Substance DPOCL CytoTools AG has received the preliminary results of the test series with the active substance DPOCL, carried out in cooperation with the Institute for Medical Virology at the University Hospital Frankfurt. The test results confirm the clearly virucidal ("virus-killing") effect of the active ingredient on the COVID-19-triggering SARS-CoV-2 pathogen. In the cell culture experiments of the university working group Medical Virology, the efficacy of DPOCL on the virus SARS-CoV-2 was investigated in combination with human CaCo-2 cells. A dose-dependent effect was found, which confirmed a more than 90% efficacy with the highest dose. Thus a virucidal efficacy of DPOCL on the virus SARS-CoV-2 has been proven. The test results underline the very good efficacy of DPOCL and, together with already available data on DPOCL, suggest that the drug is well tolerated. With the pre-clinical data of DPOCL already available, the first human trials can now be started shortly. In this human study, the use of DPOCL as a multiple daily inhalation component with physiological saline solution via commercially available inhalers will be investigated in order to bring the product to market quickly in an easily applicable form. In the company's internal test series with commercially available inhalers, the nebulization of DPOCL in saline solution has already been successfully tested. The company therefore assumes that the positive results can also be replicated in the human study that is now being conducted. This would allow the virus to be controlled directly in the lungs or in the bronchial region and the upper respiratory tract, i.e. at the virus' entry barrier into the body, at a very early stage. The good tolerability of the drug solution offers the advantage that comparatively complication-free treatment can be started at a very early stage of an infection. DPOCL is already approved as a wound healing product for the indication diabetic foot in the Indian market and is currently in the beginning of a Phase III clinical trial in Europe. In addition to the effect of DPOCL on the SARS-CoV-2 virus, the Institute of Medical Virology is also investigating its virucidal effect on influenza viruses. Should the results prove a similarly high efficacy, DPOCL could be a fundamentally new therapy for viral influenza infections - beyond the COVID-19 pandemic. Is New 90 Day High Low • Nov 06
New 90-day high: €19.90 The company is up 97% from its price of €10.10 on 07 August 2020. The German market is down 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €237 per share. Is New 90 Day High Low • Oct 14
New 90-day high: €19.50 The company is up 97% from its price of €9.90 on 16 July 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €189 per share. Reported Earnings • Oct 01
First half earnings released Over the last 12 months the company has reported total losses of €1.40m, with losses widening by 2.5% from the prior year. Is New 90 Day High Low • Sep 26
New 90-day high: €15.00 The company is up 65% from its price of €9.10 on 26 June 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 1.0% over the same period. Price Target Changed • Sep 24
Price target raised to €38.80 Up from €29.89, the current price target is provided by 1 analyst. The new target price is 188% above the current share price of €13.45. As of last close, the stock is up 43% over the past year. Announcement • Sep 18
CytoTools Examines the Effectiveness of Its Patented Active Substance DPOCL in COVID-19 Infections CytoTools AG has started studies on the efficiency of its active substance DPOCL in COVID-19 through its subsidiary CytoPharma. The test series will be carried out in cooperation with the renowned German university working group Virology of the University Hospital Frankfurt. The aim of the novel treatment is to offer the active ingredient DPOCL in the form of an inhalation solution, e.g. combined with a simple saline solution, which can be nebulized in commercially available inhalers. Tests with freely available inhalers have already been successfully completed. This would enable the virus to be controlled directly in the lungs or in the bronchial region and the upper respiratory tract, at the barrier of entry of the virus into the body, at a very early stage. The known extraordinarily good tolerability of the active ingredient solution offers the advantage here that comparatively complication-free treatment can be started at a very early stage of an infection. Announcement • Aug 27
CytoTools AG announced that it has received €3.7 million in funding from PIH Pharma Industry Holding GmbH CytoTools AG (XTRA:T5O) announced that it has received approximately €3.7 million in an equity round of funding from new investor, PIH Pharma Industry Holding GmbH for a stake on August 26, 2020. Announcement • Jun 19
CytoTools AG to Report Fiscal Year 2019 Results on Jun 30, 2020 CytoTools AG announced that they will report fiscal year 2019 results on Jun 30, 2020 